Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term treatment with Hydroxynidone capsules in chronic hepatitis B liver fibrosis
CTR20231696Phase 3Active
- Sponsor
- Gyre Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydronidone in Chronic Hepatitis B (CHB), sponsored by Gyre Pharmaceuticals. Started Aug 2023; status: active.
02
Drugs
hydronidone
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20231696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231696.